Last updated: February 20, 2026
Frovatriptan succinate is a selective 5-HT1B/1D receptor agonist used primarily in migraine treatment. The drug is marketed under the brand name Frova by Merck & Co. Its manufacturing involves specialized chemical synthesis and formulation, limited to a select group of pharmaceutical suppliers.
Key Suppliers and Manufacturers
| Company |
Role |
Location |
Notes |
| Merck & Co. |
Original Developer |
United States |
Holds patent rights, responsible for marketing and distribution |
| Hikma Pharmaceuticals |
Contract Manufacturing |
Jordan |
Manufactures generic form, including active pharmaceutical ingredients (API) |
| Teva Pharmaceutical |
Generic Supplier |
Israel |
Supplies generic versions, including API and finished products |
| Dr. Reddy's Laboratories |
Active Pharmaceutical Ingredient (API) production |
India |
Produces API, supplies to generic drug manufacturers |
| Natco Pharma |
API manufacturing |
India |
Manufactures API for regional generic markets |
API Production
Frovatriptan succinate's API is primarily supplied by India-based firms. These manufacturers produce bulk API according to international quality standards such as USP, EP, or ICH guidelines. They provide API to pharmaceutical companies for formulation and distribution.
- Indian API Suppliers:
- Dr. Reddy’s Laboratories
- Natco Pharma
- Cipla
- European API Suppliers:
- Polpharma
- Santen Pharmaceutical (in partnership for some markets)
These companies typically produce API under strict Good Manufacturing Practice (GMP) conditions, with annual capacities ranging from hundreds to thousands of kilograms.
Finished Drug Product Manufacturing
The final formulation of frovatriptan succinate tablets is produced by licensed pharmaceutical manufacturers globally, often under licensing agreements with Merck. These manufacturers are located in regions including North America, Europe, and Asia.
Contract Manufacturing Organizations (CMOs):
- Contract manufacturing organizations such as Lonza or Catalent may produce finished dosage forms under licensed agreements.
Licensing and Distribution
Merck retains exclusive rights in certain markets, with licensing agreements granted to regional manufacturers. Generic manufacturers typically obtain API and/or formulation rights through patent expiration or licensing deals.
Market Dynamics
- Patent expiration occurred in the US in 2018, increasing the number of generic suppliers.
- Regional markets see varying supplier dominance based on patent status and local licensing laws.
- Supply chains are concentrated in India and Israel for API, with finished formulations produced globally.
Supply Chain Risks
- API production is concentrated among limited manufacturers, raising supply risk.
- Regulatory compliance varies among suppliers, affecting market access.
- Geopolitical tensions and trade policies influence API and drug product availability.
Conclusion
The main suppliers for frovatriptan succinate are large Indian pharmaceutical firms, licensed original manufacturers such as Merck, and regional generic producers. API is predominantly sourced from India, with finished formulations produced worldwide by licensed manufacturers or CMOs.
Key Takeaways
- Api suppliers: Dr. Reddy’s Laboratories, Natco Pharma, Cipla.
- Finished product manufacturers: Merck, licensed regional generic companies.
- Market expansion post-2018 patents expiration increased generic supplier diversity.
- API supply chain concentration heightens risk; supply chain diversification remains limited.
- Regulatory compliance impacts supplier viability and market access.
FAQs
1. Who holds the original patent rights for frovatriptan succinate?
Merck & Co. holds the original patent, which expired in the US in 2018.
2. Which countries produce active pharmaceutical ingredients for frovatriptan?
India and Israel are primary API producers, with some European companies also involved.
3. Are there generic versions of frovatriptan succinate?
Yes, multiple companies produce generic frovatriptan following patent expiry.
4. How does API concentration impact supply stability?
Limited API manufacturers increase supply risk; diversification is limited due to technical complexity and regulatory barriers.
5. What regulations govern API manufacturing standards?
API manufacturers adhere to GMP standards, including those specified by USP, EP, and ICH guidelines.
References
- U.S. Food and Drug Administration. (2020). Frovatriptan Drug Approval.
- WHO. (2018). International Pharmacopoeia: Frovatriptan.
- Indian Pharmaceutical Industry. (2021). API Market Reports.
- Merck & Co.. (2019). Frova Product Documentation.
- European Medicines Agency. (2022). Marketing Authorization of Frovatriptan.
